A high-stakes legal fight between Regeneron and Amgen over the blockbuster eye drug Eylea is putting the U.S. patent system ...

Review Article Open access Published: 19 April 2018 Review Article TRPM2: a candidate therapeutic target for treating neurological diseases Jillian Corinne Belrose & Michael Frederick Jackson Acta ...

Enzyme mechanisms articles from across Nature Portfolio Enzyme mechanisms are the chemical transformations, and the steps within them, generated by enzymatic action on substrates.

FDA approves subcutaneous form of J&J and Genmab’s anti-CD38 drug Darzalex for the treatment of multiple myeloma, relieving pressure from Sanofi’s recently launched Sarclisa ...

Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...

A new year means a new Fierce Biotech Fundraising Tracker to record the significant amounts of venture capital being funneled into the industry. | The Fierce Biotech Fundraising Tracker records ...

Advanced Enzyme Technologies Share Price Today 10 Jul 2025: Track Advanced Enzyme Technologies share price today on NSE/BSE with real-time updates. Check stock performance, fundamentals, market ...